A phase 1/2 open-label, single ascending dose trial of a self-complementing optimized adeno-associated virus serotype 8 Factor IX gene therapy (AskBio009) in adults with haemophilia B

Trial Profile

A phase 1/2 open-label, single ascending dose trial of a self-complementing optimized adeno-associated virus serotype 8 Factor IX gene therapy (AskBio009) in adults with haemophilia B

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs AskBio 009 (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Asklepios BioPharmaceutical; Baxter Healthcare Corporation
  • Most Recent Events

    • 07 Sep 2016 Planned End Date changed from 1 Nov 2029 to 1 Nov 2030.
    • 07 Sep 2016 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2030.
    • 10 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top